Hassoun, Hani

Publications

Sort by

Co-Author Network

selected publications

Accelerated single cell seeding in relapsed multiple myeloma. Nature communications. 2020 Academic Article GET IT
Times cited: 42
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2020 Academic Article GET IT
Times cited: 9
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. Leukemia & lymphoma. 2020 Article GET IT
Monoclonal gammopathy-associated thrombotic microangiopathy. American journal of hematology. 2019 Article GET IT
Times cited: 28
Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia & lymphoma. 2018 Letter GET IT
Times cited: 14
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 33
Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2017 Academic Article GET IT
Times cited: 41
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 9
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 1
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 54
Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia & lymphoma. 2016 Article GET IT
Times cited: 7
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 12
Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical biochemistry. 2016 Academic Article GET IT
Times cited: 56
Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2016 Academic Article GET IT
Times cited: 50
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood. 2016 Article GET IT
Times cited: 14
Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 5
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone marrow transplantation. 2016 Academic Article GET IT
Times cited: 47
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 23
Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nature reviews. Clinical oncology. 2015 Information Resource GET IT
Times cited: 95
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Academic Article GET IT
Times cited: 59
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014 Academic Article GET IT
Times cited: 70
Current strategies for treatment of relapsed/refractory multiple myeloma. Expert review of hematology. 2014 Information Resource GET IT
Times cited: 52
Challenging diagnosis of intra-diverticular colonic adenocarcinoma with submucosal localization. International journal of colorectal disease. 2013 Article GET IT
Times cited: 2
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance. Leukemia. 2013 Article GET IT
Times cited: 11
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone marrow transplantation. 2013 Academic Article GET IT
Times cited: 27
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2012 Academic Article GET IT
Times cited: 74
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 2012 Academic Article GET IT
Times cited: 84
Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 44
Lenalidomide after stem-cell transplantation for multiple myeloma. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 994
Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clinical lymphoma, myeloma & leukemia. 2011 Academic Article GET IT
Times cited: 24
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia & lymphoma. 2011 Academic Article GET IT
Times cited: 11
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 350
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM : monthly journal of the Association of Physicians. 2011 Academic Article GET IT
Times cited: 39
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2011 Academic Article GET IT
Times cited: 18
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Academic Article GET IT
Times cited: 134
Osteomalacia due to adult Fanconi syndrome in multiple myeloma. Leukemia & lymphoma. 2011 Article GET IT
Times cited: 2
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 247
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. 2009 GET IT
Times cited: 270
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. British journal of haematology. 2008 Academic Article GET IT
Times cited: 100
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone marrow transplantation. 2008 Academic Article GET IT
Times cited: 56
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British journal of haematology. 2007 Academic Article GET IT
Times cited: 114
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Academic Article GET IT
Times cited: 251
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia. 2006 Academic Article GET IT
Times cited: 8
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. British journal of haematology. 2006 Academic Article GET IT
Times cited: 42
Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. The Journal of experimental medicine. 2005 Academic Article GET IT
Times cited: 377
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone marrow transplantation. 2005 Academic Article GET IT
Times cited: 17
Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer immunity. 2003 Academic Article GET IT
Times cited: 117
Allopurinol-induced pure red cell aplasia. American journal of hematology. 2003 Article GET IT
Times cited: 5
Possible association between hairy cell leukemia and Behçet's disease. Southern medical journal. 2003 Article GET IT
Times cited: 5
beta-Spectrin S(ta) Bárbara: a novel frameshift mutation in hereditary spherocytosis associated with detectable levels of mRNA and a germ cell line mosaicism. British journal of haematology. 2001 Academic Article GET IT
Times cited: 8
Targeted inactivation of murine band 3 (AE1) gene produces a hypercoagulable state causing widespread thrombosis in vivo. Blood. 1998 Academic Article GET IT
Times cited: 35
Complete deficiency of glycophorin A in red blood cells from mice with targeted inactivation of the band 3 (AE1) gene. Blood. 1998 Academic Article GET IT
Times cited: 75
Beta-spectrin Promiss-ao: a translation initiation codon mutation of the beta-spectrin gene (ATG --> GTG) associated with hereditary spherocytosis and spectrin deficiency in a Brazilian family. Blood. 1998 Article GET IT
Times cited: 13
Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood. 1997 Academic Article GET IT
Times cited: 62
A novel mobile element inserted in the alpha spectrin gene: spectrin dayton. A truncated alpha spectrin associated with hereditary elliptocytosis. The Journal of clinical investigation. 1994 Academic Article GET IT
Times cited: 37

more ...

less ...

Background

education and training

M.D., University of Paris Medical School (France) 83

Contact

full name

Hani Hassoun

VIVO Weill Cornell Medical College

Hani Hassoun Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name